- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
High-Dose Influenza Vaccine Highly Effective in Preventing Hospitalizations: Study
![High-Dose Influenza Vaccine Highly Effective in Preventing Hospitalizations: Study High-Dose Influenza Vaccine Highly Effective in Preventing Hospitalizations: Study](https://medicaldialogues.in/h-upload/2023/04/17/750x450_207564-seasonal-influenza-1.webp)
A new study discovered that the high-dose quadrivalent influenza vaccine (QIV-HD) outperforms the standard-dose version (QIV-SD) in preventing recurrent hospitalizations among older adults of 65 to 79 years. The findings were published in the Clinical Microbiology and Infection.
This post-hoc analysis of an open-label, randomized trial enrolled a total of 12,477 participants from October to November of 2021 and followed them until May 31, 2022. The participants were randomly assigned to receive either QIV-HD or QIV-SD. The outcomes were monitored 14 days after vaccination and focused on various outcomes, including hospitalizations for pneumonia or influenza, respiratory and cardio-respiratory hospitalizations, cardiovascular hospitalizations, all-cause hospitalizations and all-cause mortality.
The results from this study revealed a significant association between QIV-HD and lower incidence rates of hospitalizations for pneumonia or influenza (10 vs. 33 events) and all-cause hospitalizations (647 vs. 742 events) when compared to QIV-SD. Also, the benefits of QIV-HD were consistently observed over time even before the onset of active influenza transmission.
The data showed that the first significant reduction in hospitalizations for pneumonia or influenza occurred by calendar week 3 of 2022, while the influenza test positivity rate reached over 10% only in calendar week 10 of 2022. This indicates that the effectiveness of QIV-HD extends beyond the active influenza circulation which suggests a broader protective effect. This post-hoc analysis indicates that QIV-HD may offer a more active defense against recurrent hospitalizations than QIV-SD, with trends favoring the high-dose vaccine evident independently of influenza circulation levels.
Source:
Johansen, N. D., Modin, D., Skaarup, K. G., Nealon, J., Samson, S., Dufournet, M., Loiacono, M. M., Harris, R. C., Larsen, C. S., Reimer Jensen, A. M., Landler, N. E., Claggett, B. L., Solomon, P. S. D., Landray, P. M. J., Gislason, P. G. H., Køber, P. L., Stæhr Jensen, P. J. U., Sivapalan, P., Vestergaard, L. S., … Biering-Sørensen, P. T. (2024). Effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine against recurrent hospitalisations and mortality in relation to influenza circulation: a post-hoc analysis of the DANFLU-1 randomised clinical trial. In Clinical Microbiology and Infection. Elsevier BV. https://doi.org/10.1016/j.cmi.2024.01.017
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751